



(51) International Patent Classification:

C07D 471/10 (2006.01) **A61P 3/10** (2006.01)
A61K 31/438 (2006.01) **A61P 1/16** (2006.01)

(21) International Application Number:

PCT/IB2010/054908

(22) International Filing Date:

29 October 2010 (29.10.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/259,823 10 November 2009 (10.11.2009) US

(71) **Applicant** (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **BAGLEY, Scott, William** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **GRIFFITH, David, Andrew** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **KUNG, Daniel, Wei-Shung** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US).

(74) **Agent:** **BENSON, Gregg, C.**; c/o Pfizer Global Research & Development Eastern Point Road, MS 9114, Groton, Connecticut 06340 (US).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i))

[Continued on next page]

(54) **Title:** N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

(I)

(57) **Abstract:** The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R¹, R², R³ and R⁴ are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal.



-
- Published:**
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
 - *with international search report (Art. 21(3))*
 - *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
 - *with sequence listing part of description (Rule 5.2(a))*